PMID- 37899317
OWN - NLM
STAT- MEDLINE
DCOM- 20231031
LR  - 20231031
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 52
IP  - 11
DP  - 2023 Nov 8
TI  - [Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases].
PG  - 1120-1125
LID - 10.3760/cma.j.cn112151-20230203-00092 [doi]
AB  - Objective: To investigate the clinicopathological features, immunophenotype, 
      molecular features and differential diagnosis of primary synovial sarcoma of the 
      lung (PSSL). Methods: Twelve cases of PSSL were collected at Henan Provincial 
      People's Hospital, during May 2010 and April 2021, and their clinicopathological 
      parameters were summarized. SS18-SSX, H3K27Me3, and SOX2 were added to the 
      original immunomarkers to evaluate their diagnostic value for PSSL. Results: The 
      age of 12 patients when diagnosed ranged from 32 to 75 years (mean of 50 years). 
      There were 7 males and 5 females, 2 left lung cases and 10 right lung cases. Of 
      the 6 patients who underwent surgical resection, five cases were confined to lung 
      tissue (T1), one case had mediastinal invasion (T3), two cases had regional lymph 
      node metastasis (N1), and none had distal metastasis. Microscopically, 11 cases 
      showed monophasic spindle cell type and one case showed biphasic type composed of 
      mainly epithelial cells consisting of cuboidal to columnar cells with glandular 
      and cribriform structures. It was difficult to make the diagnosis by using the 
      biopsy specimens. Immunohistochemistry (IHC) showed CKpan expression in 8 of 12 
      cases; EMA expression in 11 of 12 case; TLE1 expression in 8 of 12 cases; S-100 
      protein expression in two of 12 cases; various expression of bcl-2 and vimentin 
      in 12 cases, but no expression of SOX10 and CD34 in all the cases. The Ki-67 
      index was 15%-30%. The expression of SS18-SSX fusion antibody was diffusely and 
      strongly positive in all 12 cases. SOX2 was partially or diffusely expressed in 8 
      of 12 cases, with strong expression in the epithelial component. H3K27Me3 was 
      absent in 3 of 12 cases. SS18 gene translocation was confirmed by fluorescence in 
      situ hybridization (FISH) test in all 12 samples. Six cases underwent surgery and 
      postoperative chemotherapy, while the other six cases had chemotherapy alone. Ten 
      patients were followed up after 9-114 months, with an average of 41 months and a 
      median of 26 months. Five patients survived and five died of the disease within 
      two years. Conclusions: PSSL is rare and has a broad morphological spectrum. IHC 
      and molecular tests are needed for definitive diagnosis. Compared with current 
      commonly used IHC markers, SS18-SSX fusion antibody has better sensitivity to 
      PSSL, which could be used as an alternative for FISH, reverse 
      transcription-polymerase chain reaction or next generation sequencing in the 
      diagnosis of PSSL.
FAU - Zhang, X W
AU  - Zhang XW
AD  - Department of Pathology, Henan Provincial People's Hospital, People's Hospital of 
      Zhengzhou University, Zhengzhou 450003, China.
FAU - Wei, J G
AU  - Wei JG
AD  - Department of Pathology, Shaoxing People's Hospital of Zhejiang Province,Shaoxing 
      312000, China.
FAU - Sun, J P
AU  - Sun JP
AD  - Department of Pathology, Zhengzhou Yihe Hospital, Zhengzhou 450000, China.
FAU - Xu, Z G
AU  - Xu ZG
AD  - Department of Pathology, Henan Provincial People's Hospital, People's Hospital of 
      Zhengzhou University, Zhengzhou 450003, China.
FAU - Cheng, Q
AU  - Cheng Q
AD  - Department of Pathology, Henan Provincial People's Hospital, People's Hospital of 
      Zhengzhou University, Zhengzhou 450003, China.
FAU - Zhang, L
AU  - Zhang L
AD  - Department of Pathology, Henan Provincial People's Hospital, People's Hospital of 
      Zhengzhou University, Zhengzhou 450003, China.
FAU - Kong, L F
AU  - Kong LF
AD  - Department of Pathology, Henan Provincial People's Hospital, People's Hospital of 
      Zhengzhou University, Zhengzhou 450003, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histones)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Repressor Proteins)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - *Sarcoma, Synovial/genetics/surgery/diagnosis
MH  - In Situ Hybridization, Fluorescence
MH  - Histones/genetics
MH  - Proto-Oncogene Proteins/genetics/metabolism
MH  - Oncogene Proteins, Fusion/genetics
MH  - Repressor Proteins/genetics/metabolism
MH  - Lung/pathology
MH  - *Lung Neoplasms
EDAT- 2023/10/30 00:42
MHDA- 2023/10/31 06:42
CRDT- 2023/10/29 23:29
PHST- 2023/10/31 06:42 [medline]
PHST- 2023/10/30 00:42 [pubmed]
PHST- 2023/10/29 23:29 [entrez]
AID - 10.3760/cma.j.cn112151-20230203-00092 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2023 Nov 8;52(11):1120-1125. doi: 
      10.3760/cma.j.cn112151-20230203-00092.